LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director
05 Februar 2024 - 2:00PM
Business Wire
William Kozy will remain Board Chair
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology
company, today announced its Board of Directors named Vladimir A.
Makatsaria as the Company’s Chief Executive Officer (CEO) and a
member of the Board of Directors, effective March 1, 2024.
Makatsaria most recently served as Company Group Chairman at
Johnson & Johnson MedTech, leading its global Ethicon surgery
business.
“Vlad is a respected leader in the medical device industry with
a proven reputation for delivering results, driving innovation and
building great teams,” said Bill Kozy, LivaNova Board Chair. “The
Board and I have great confidence that Vlad is the right CEO to
advance the Company’s strategic plan and achieve our goals for
long-term growth.”
Makatsaria will succeed Kozy, who has served as Interim CEO
since April 2023. Kozy will continue in his role as LivaNova Board
Chair.
“I look forward to working with the global team to deliver
meaningful medical technologies to the patients we serve and to
achieve LivaNova’s full potential,” said Makatsaria. “I would like
to thank the Board of Directors and Bill Kozy for the opportunity
to serve as CEO of LivaNova.”
Makatsaria’s nearly 30-year career has been in healthcare with
executive leadership roles at Johnson & Johnson, spanning
across various technologies and geographies. He has served as
Chairman of the Asia Pacific Medical Technology Association
(APACMed) and as an Advisory Board Member to Singapore Management
University. Makatsaria holds a Bachelor of Arts in Physiology, a
Master of Healthcare Administration and a Master of Business
Administration from the University of Minnesota.
About LivaNova
LivaNova PLC is a global medical technology company built on
nearly five decades of experience and a relentless commitment to
provide hope for patients and their families through medical
technologies, delivering life-changing improvements for both the
Head and Heart. Headquartered in London, LivaNova employs
approximately 2,900 employees and has a presence in more than 100
countries for the benefit of patients, healthcare professionals and
healthcare systems worldwide. For more information, please visit
www.livanova.com.
Safe Harbor Statement
This news release contains “forward-looking statements”
concerning the Company’s goals, beliefs, expectations, strategies,
objectives, plans, underlying assumptions and other statements that
are not necessarily based on historical facts. These statements
include, but are not limited to, statements regarding the executive
leadership of the Company. Actual events may differ materially from
those indicated in our forward-looking statements as a result of
various factors, including those factors set forth in Item 1A of
the Company’s most recent Annual Report on Form 10-K, as
supplemented by any risk factors contained in Quarterly Reports on
Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no
obligation to update the information contained in this press
release to reflect subsequently occurring events or
circumstances.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240205142599/en/
LivaNova Investor Relations and Media Contacts +1
281-895-2382
Briana Gotlin Director, Investor Relations
InvestorRelations@livanova.com
Deanna Wilke VP, Corporate Communications
Corporate.Communications@livanova.com
LivaNova (NASDAQ:LIVN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
LivaNova (NASDAQ:LIVN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024